Clinical experience with excitatory amino acid antagonist drugs
about
Excitatory amino acid inhibitors for traumatic brain injuryExcitatory amino acid antagonists for acute strokeExcitatory amino acid inhibitors for traumatic brain injuryCurrent understanding of TRPM7 pharmacology and drug development for strokeKetamine in adult cardiac surgery and the cardiac surgery Intensive Care Unit: an evidence-based clinical reviewThe fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazineFrom PCP to MXE: a comprehensive review of the non-medical use of dissociative drugsComplementary roles of neurotrophin 3 and a N-methyl-D-aspartate antagonist in the protection of noise and aminoglycoside-induced ototoxicityAMPA/kainate receptors in mouse spinal cord cell-specific display of receptor subunits by oligodendrocytes and astrocytes and at the nodes of Ranvier.What's New in Traumatic Brain Injury: Update on Tracking, Monitoring and TreatmentAn N-methyl-D-aspartate receptor channel blocker with neuroprotective activity.Potential future neuroprotective therapies for neurodegenerative disorders and stroke.Neuroprotection in acute ischaemic stroke. II: Clinical potential.A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury.The role of dextromethorphan in pain control.Inverse relationship between seizure expression and extrasynaptic NMDAR function following chronic NMDAR inhibition.Neuraxial infusion in patients with chronic intractable cancer and noncancer pain.Recent advances in the acute management of ischaemic stroke.Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective.E-p-methoxycinnamic acid protects cultured neuronal cells against neurotoxicity induced by glutamate.Assessment of cognitive and motor deficits in a marmoset model of stroke.Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL.N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.Inhibition of WNK3 Kinase Signaling Reduces Brain Damage and Accelerates Neurological Recovery After Stroke.Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury.Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.Clinical pharmacological issues in the development of acute stroke therapies.The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemiaSynaptic and extrasynaptic plasticity in glutamatergic circuits involving dentate granule cells following chronic N-methyl-D-aspartate receptor inhibition.Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia.Neuroprotective strategies to avert seizure-induced neurodegeneration in epilepsy.The past and future of neuroprotection in cerebral ischaemic stroke.Vascular dementia: pharmacological treatment approaches and perspectivesRab-mediated endocytosis: linking neurodegeneration, neuroprotection, and synaptic plasticity?Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.Neuroprotectants in stroke therapy.Synaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in an in vitro model of limbic epileptogenesis.The mechanisms of brain ischemic insult and potential protective interventions.
P2860
Q24203796-B9A2A779-C01E-4806-9C24-0908E74733B6Q24248015-AD10BAF4-AA7C-44B0-8F90-0C91AC5CB12BQ24250201-B6723B23-4AF9-43DE-A48C-10CB3AD187ADQ26853706-6977CCD9-02C4-4A63-8780-DE2BE4A2EC87Q27008948-74FF9ACB-F79C-410F-953D-F9879A9383D4Q28069442-89BB0221-1D05-4029-B7DA-214D572A60B7Q28210391-8D29614F-859A-441B-B747-BFC437CA5038Q28236984-11CC3244-E544-4418-B02A-BC435CDABA36Q30504118-CC10CA69-6D44-4A40-8FE4-DBE785DB5D21Q30764884-A20AE9EA-6389-4C87-8455-6C5648F4278FQ30959630-53C1B440-588E-4E4A-9622-B2F1B79BFC39Q30983394-46906E2B-7974-4C23-B0B9-C4C6F5DE9F1AQ33687436-1EEDBD33-730A-42D4-9C01-86EC0E9B0A99Q33747433-404966E1-B333-4A25-A2AB-1E4C693711DBQ33889453-EA80D6E7-9FE6-4839-84D4-6F0CED0F2112Q33956193-6F7D663E-6DFD-4B1C-96ED-A970082616FBQ34015816-1FC2B163-67A8-4A65-A81E-20C3BDE771CCQ34222812-1B62BABA-721D-4279-BAD2-C8056BED482EQ34292998-7B26B08A-04A1-4B62-A0E3-5C5247A390A9Q34941187-0B7DFDAD-9595-4BA9-AB28-1DCEA4C67D33Q35044198-8FDF2A90-3A00-4362-A0E0-227EFFA885A6Q35090292-439C0887-C2E8-41FF-B31A-915575C06624Q35700595-B6B314E4-0CBD-4EAF-AA08-B3270C7D988EQ36068372-D31CD010-1093-4555-9EB4-92B8BF009DE8Q36158952-CFFFC485-0EE9-496B-8287-0F707FCF2D77Q36276655-8196D27F-A0E1-4B10-9E5D-B5744ADB64F9Q36298111-78C29F66-CB58-42F4-815E-A5A3125014F7Q36302850-E59338C1-72C5-4402-8F88-72C45B32E177Q36496990-E787DE7A-C04C-464D-BE5C-5FD2A605490CQ36690082-C6EC1072-502A-4D3F-8B37-209CDC7E2BB3Q36700706-97D68646-9E43-4C0C-877F-F974C4E30EF0Q36817047-710EB19D-44E6-46E9-B005-4775591A185FQ36850257-71F5784F-511C-4A37-A853-80375716188CQ36961362-99F6AEE9-BA6E-4066-8F51-3A5CD0BC5DECQ37017429-F89881F0-E4D9-4F33-9B89-97E14F714549Q37031233-C0AFD8F1-83CE-4006-A72B-A303B3ED6EECQ37120231-5EF70BCF-FC53-44FE-92FB-ED26D939058BQ37123385-8508914A-EF26-4582-BD8E-C9BE27B0D665Q37430885-B3E2BA70-FBAE-4E8F-ADF5-5E697F47DDCCQ37485957-75AFC5F6-C0BC-452E-812C-A5CDB6803030
P2860
Clinical experience with excitatory amino acid antagonist drugs
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Clinical experience with excitatory amino acid antagonist drugs
@ast
Clinical experience with excitatory amino acid antagonist drugs
@en
Clinical experience with excitatory amino acid antagonist drugs
@nl
type
label
Clinical experience with excitatory amino acid antagonist drugs
@ast
Clinical experience with excitatory amino acid antagonist drugs
@en
Clinical experience with excitatory amino acid antagonist drugs
@nl
prefLabel
Clinical experience with excitatory amino acid antagonist drugs
@ast
Clinical experience with excitatory amino acid antagonist drugs
@en
Clinical experience with excitatory amino acid antagonist drugs
@nl
P3181
P356
P1433
P1476
Clinical experience with excitatory amino acid antagonist drugs
@en
P2093
P304
P3181
P356
10.1161/01.STR.26.3.503
P407
P577
1995-03-01T00:00:00Z